Gastrointestinal stromal tumors (GISTs) are one of the most common mesenchymal tumors characterized by different molecular alterations that lead to specific clinical presentations and behaviors. In the last twenty years, thanks to the discovery of these mutations, several new treatment options have emerged. This review provides an extensive overview of GISTs’ molecular pathways and their respective tailored therapeutic strategies. Furthermore, current treatment strategies under investigation and future perspectives are analyzed and discussed.
25 August 2026 in Journal of Translational Medicine
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for several solid tumors. Among the mechanisms investigated to explain variabi